André, T, Falcone, A, Shparyk, Y, Moiseenko, F, Polo-Marques, E, Csöszi, T, Campos-Bragagnoli, A, Liposits, G, Chmielowska, E, Aubel, P, Martín, L, Fougeray, R, Amellal, N & Saunders, M P 2023, ' Trifluridine–tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE) : a randomised, open-label phase 3 study ', The Lancet. Gastroenterology & hepatology, vol. 8, no. 2, pp. 133-144 . https://doi.org/10.1016/S2468-1253(22)00334-X